ARCHIVES

Longterm Followup Finds Taxotere Improves Survival

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

FDA Accepts Advisory Committee’s Recommendations On NDA, Labeling

October 26, 1979

Novartis Submits Gleevec Data To FDA Seeking Approval For Use In GI Tumors.

October 26, 2001

NKTR-102 Shows 29 Percent Response in Phase II Study

September 30, 2011

Lasker Official Urges Congressional Support Of NCI Bypass Budget

April 20, 1990

Clearinghouse Finds Seven Compounds Are Carcinogenic, Human Threat

September 1, 1978

ODAC Supports Approval For Taxotere In Breast Cancer, Hycamtin In Lung Cancer

June 5, 1998